Edition:
United States

Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

1.41USD
2 Dec 2016
Change (% chg)

$0.01 (+0.71%)
Prev Close
$1.40
Open
$1.40
Day's High
$1.46
Day's Low
$1.37
Volume
2,936,708
Avg. Vol
1,532,550
52-wk High
$2.35
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'
Thursday, 25 Aug 2016 06:20am EDT 

Arena Pharmaceuticals Inc : Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq . Notification is currently under investigation . Co and Eisai have 45 days from receipt of notification to file a patent infringement suit against ANDA filer .Patent infringement suit would result in stay of FDA approval of ANDA under statutory guidelines.  Full Article

Arena Pharmaceuticals reports Q2 loss per share $0.11
Monday, 8 Aug 2016 04:01pm EDT 

Arena Pharmaceuticals Inc : Arena Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 revenue $9.5 million versus I/B/E/S view $10.4 million . Q2 loss per share $0.11 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Arena Pharma, EISAI announce FDA approval of BELVIQ XR extended-release tablets
Tuesday, 19 Jul 2016 08:26am EDT 

Arena Pharmaceuticals Inc : BELVIQ XR is expected to be available in fall of 2016. . Arena pharmaceuticals inc says in connection with approval, arena will receive a $10 million milestone payment. . EISAI Inc and Arena Pharmaceuticals announce FDA approval of Belviq XR (lorcaserin HCL) extended-release tablets .In connection with approval, arena will receive a $10 million milestone payment.  Full Article

Eisai, Arena announce regulatory approval of VENESPRI in Mexico
Thursday, 14 Jul 2016 08:05am EDT 

Arena Pharmaceuticals Inc : Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI® (lorcaserin HCl) in Mexico . In connection with the approval, Arena will receive a $1 million milestone payment . In connection with the approval, Arena will receive a $1 million milestone payment .VENESPRI® is expected to become available later this year.  Full Article

Arena Pharmaceuticals to emphasize on its proprietary clinical stage pipeline
Thursday, 30 Jun 2016 04:05pm EDT 

Arena Pharmaceuticals: Arena Pharmaceuticals Inc says strategic shifting of priorities to emphasize its proprietary clinical stage pipeline . Arena Pharmaceuticals Inc says implementation of additional cost reductions to streamline organization to support its development programs . Arena pharmaceuticals inc says will reduce its us workforce by approximately 100 employees, or 73%, primarily in areas of research, manufacturing and G&A . Estimates cost reductions to result in reduced cash expenditures for personnel by about $17 million . Plans to implement additional cost control measures to further reduce expenditures, including reductions at Swiss manufacturing facility .As a result of us workforce reduction, estimates it will incur restructuring charges, primarily in q2 of 2016, of about $6.1 million.  Full Article

Arena Pharmaceuticals files for mixed shelf of up to $250 mln
Tuesday, 14 Jun 2016 04:18pm EDT 

Arena Pharmaceuticals Inc :Arena Pharmaceuticals Inc files for mixed shelf of up to $250 million - SEC filing.  Full Article

Arena Pharmaceuticals Q1 loss per share $0.09
Monday, 9 May 2016 04:27pm EDT 

Arena Pharmaceuticals Inc : Amit munshi appointed chief executive officer . Arena pharmaceuticals reports first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.09 . Q1 revenue $9.8 million versus i/b/e/s view $9 million .Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in Schizophrenia
Tuesday, 12 Jan 2016 04:05pm EST 

Arena Pharmaceuticals Inc:Says the company and Arena Pharmaceuticals, Inc have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors.New partnership further supports Boehringer Ingelheim's CNS pipeline projects.  Full Article

Arena Pharmaceuticals Inc initiates a phase 1b clinical trial of APD371
Thursday, 29 Oct 2015 08:00am EDT 

Arena Pharmaceuticals Inc:Says initiation of patient dosing in a Phase 1b multiple-ascending dose clinical trial of APD371.Says randomized, double-blind, placebo-controlled Phase 1b clinical trial will enroll approximately 36 healthy adults to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD371.  Full Article

Arena Pharmaceuticals Inc to lay off 35 pct of U.S. workers - Reuters
Tuesday, 27 Oct 2015 06:09pm EDT 

Arena Pharmaceuticals Inc:Arena Pharmaceuticals Inc will shelve some trials related to its weight-loss drug and lay off about 80 employees, or 35 percent of its U.S. workforce, to cut costs and focus on other drugs under development - RTRS.San Diego-based Arena said it would incur restructuring charges of about $3.3 million related to the U.S. layoffs, mostly in the fourth quarter. The layoffs would save the company about $11 million a year, it said on Tuesday - RTRS.Further cost reductions are likely to follow at the company's manufacturing plant in Switzerland - RTRS.Arena will not proceed at present with "certain lifecycle management programs" for its main drug, the anti-obesity treatment Belviq, sales of which have been underwhelming since its approval in 2012 by the U.S. Food and Drug Administration - RTRS.  Full Article

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.05

* Arena Pharmaceuticals reports third quarter 2016 financial results and provides corporate update